CVS Health Corp. 2024 Q2 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. CVS Health operates four reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. The company serves approximately 90 million plan members through its pharmacy benefits manager and over 36 million people through health insurance products. As of June 30, 2024, the company operated more than 9,000 retail locations and 1,000+ walk-in medical clinics.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | 2024 (YTD) | 2023 (YTD) | Change |
|---|---|---|---|
| Total Revenues | $179.7 billion | $174.2 billion | +3.1% |
| Net Income (Attributable to CVS) | $2.9 billion | $4.0 billion | -28.6% |
| Diluted EPS | $2.28 | $3.13 | -27.2% |
| Operating Income | $5.3 billion | $6.7 billion | -20.4% |
| Adjusted Operating Income | $6.7 billion | $8.9 billion | -24.3% |
| Operating Cash Flow | $8.0 billion | $13.3 billion | -40.1% |
| Cash & Equivalents | $12.5 billion | $8.2 billion | +52.0% |
| Total Debt (Long-term + Current) | $66.4 billion | $61.4 billion | +8.1% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3.1% year-over-year, driven by a 23.4% increase in Premiums revenue (Health Care Benefits) and 43.8% growth in Services revenue. This was partially offset by a 7.4% decline in Products revenue.
- Profitability Decline: Net income dropped 28.6% primarily due to higher health care costs and increased utilization in the Health Care Benefits segment. Operating income fell 20.4%.
- Health Care Benefits Segment: The Medical Benefit Ratio (MBR) increased to 90.0% (from 85.4% in 2023), driven by elevated utilization in Medicare Advantage and higher acuity in Medicaid following the resumption of redeterminations.
- Health Services Segment: Revenue declined 9.2% due to the loss of a large client and continued price improvements shared with clients. Pharmacy claims processed decreased 19.7%.
- Pharmacy & Consumer Wellness: Revenue grew 3.3% driven by prescription volume (+3.4%) and drug mix, though front store same-store sales declined 3.1% due to soft consumer demand and lower COVID-19 test kit sales.
- One-Time Items: The prior year included a $496 million restructuring charge and a $349 million loss on assets held for sale (LTC business), which were absent in the current period.
Guidance, Outlook, and Risks
- Utilization Pressures: Management expects continued elevated utilization in Medicare Advantage programs to pressure the Health Care Benefits segment for the remainder of 2024. There is a risk of recording a Medicare premium deficiency reserve in Q3 2024.
- Medicaid Costs: The Medicaid business faces medical cost pressures due to higher-than-expected acuity; it is uncertain when state rate updates will fully offset these costs.
- PBM Regulation: Legislative and regulatory activity regarding PBM practices continues, potentially limiting the ability to offer pricing that includes retail network "spread."
- GLP-1 Supply: Supply disruptions for GLP-1 drugs could impact product mix and the company's ability to deliver savings to clients.
- Legal Proceedings: The company is involved in significant litigation regarding opioid settlements (accrued $5.3 billion in 2022), PBM practices, and Medicare risk adjustment audits (RADV). A $100 million opioid litigation charge was recorded in the first half of 2024.
Investor Verification Checklist
- Medical Benefit Ratio (MBR): Verify the sustainability of the 90.0% MBR and the potential impact of a Q3 Medicare premium deficiency reserve on full-year earnings.
- Client Concentration: Assess the long-term impact of the "large client" loss on the Health Services segment's revenue and claim volume.
- Debt Service: Review the impact of new long-term debt issuances ($5.0 billion in May 2024) on interest expense and future cash flows.
- Regulatory Exposure: Monitor developments in PBM legislation and CMS RADV audit methodologies for potential retroactive premium refunds.
- Share Repurchases: Confirm the remaining authorization under the 2021 Repurchase Program ($1.5 billion) and the pace of future buybacks given the current cash flow environment.